For information, the company have announced that TRYbeCA-1 Phase 3 Trial did not meet its primary endpoint in Eryaspase in patients with second-line advanced pancreatic cancer and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes
 
Status Suspended
Decision Selected
Process STA 2018
ID number 3781

Timeline

Key events during the development of the guidance:

Date Update
01 February 2022 Suspended. For information, the company have announced that TRYbeCA-1 Phase 3 Trial did not meet its primary endpoint in Eryaspase in patients with second-line advanced pancreatic cancer and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes
01 April 2020 Topic has been referred

For further information on our processes and methods, please see our CHTE processes and methods manual